SG11201503560TA - Bendamustine derivatives and methods of using same - Google Patents

Bendamustine derivatives and methods of using same

Info

Publication number
SG11201503560TA
SG11201503560TA SG11201503560TA SG11201503560TA SG11201503560TA SG 11201503560T A SG11201503560T A SG 11201503560TA SG 11201503560T A SG11201503560T A SG 11201503560TA SG 11201503560T A SG11201503560T A SG 11201503560TA SG 11201503560T A SG11201503560T A SG 11201503560TA
Authority
SG
Singapore
Prior art keywords
methods
same
bendamustine
bendamustine derivatives
derivatives
Prior art date
Application number
SG11201503560TA
Other languages
English (en)
Inventor
Roger P Bakale
Peter D Brown
Jian Chen
Anthony S Drager
Rachel Y Labell
Robert E Mckean
Piyush R Patel
Renee C Roemmele
Original Assignee
Ignyta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ignyta Inc filed Critical Ignyta Inc
Publication of SG11201503560TA publication Critical patent/SG11201503560TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
SG11201503560TA 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same SG11201503560TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (1)

Publication Number Publication Date
SG11201503560TA true SG11201503560TA (en) 2015-06-29

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201503560TA SG11201503560TA (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Country Status (17)

Country Link
US (7) US9452988B2 (pt)
EP (1) EP2917183A1 (pt)
JP (1) JP6262246B2 (pt)
KR (1) KR20150086308A (pt)
AR (1) AR093457A1 (pt)
AU (1) AU2013342015B2 (pt)
BR (1) BR112015010501A2 (pt)
CA (1) CA2890462A1 (pt)
CL (1) CL2015001246A1 (pt)
EA (1) EA029706B1 (pt)
HK (2) HK1215701A1 (pt)
IL (1) IL238662A (pt)
MX (1) MX2015005805A (pt)
PH (1) PH12015501024A1 (pt)
SG (1) SG11201503560TA (pt)
TW (1) TWI598341B (pt)
WO (1) WO2014075035A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
AU2013342015B2 (en) * 2012-11-12 2016-11-24 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2968153B1 (en) 2013-03-12 2018-05-02 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
EP3484519A1 (en) * 2016-07-13 2019-05-22 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW201938169A (zh) 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US20210330643A1 (en) 2018-07-31 2021-10-28 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2004518776A (ja) * 2000-12-01 2004-06-24 エンゾン，インコーポレーテッド テトラパルテートプロドラッグ
US20060165987A1 (en) * 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
JP5537753B2 (ja) * 2007-11-28 2014-07-02 セレーター ファーマスーティカルズ、インク． 改良されたタキサン送達システム
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
CA2738855A1 (en) * 2008-09-29 2010-04-01 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
EA020354B1 (ru) * 2008-12-03 2014-10-30 Астеллас Дойчланд Гмбх Пероральные лекарственные формы бендамустина
EP2575784B1 (en) 2010-06-02 2018-08-08 Astellas Deutschland GmbH Oral dosage forms of bendamustine
TWI455722B (zh) 2010-06-04 2014-10-11 Pfizer Vaccines Llc 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
DE102010055499A1 (de) 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
LT2707030T (lt) 2011-05-09 2020-07-10 Mayo Foundation For Medical Education And Research Vėžio gydymas
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
SI2656843T1 (sl) 2012-04-26 2015-06-30 Helmut Schickaneder Estri bendamustina in povezane spojine ter njihova medicinska uporaba
UA117809C2 (uk) 2012-06-19 2018-10-10 Хельмут Шикканедер Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
AU2013299641A1 (en) 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
AU2013342015B2 (en) * 2012-11-12 2016-11-24 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
US20160016912A1 (en) 2016-01-21
JP6262246B2 (ja) 2018-01-17
TW201439069A (zh) 2014-10-16
CN105051016A (zh) 2015-11-11
US9913827B2 (en) 2018-03-13
EA029706B1 (ru) 2018-05-31
EP2917183A1 (en) 2015-09-16
AU2013342015B2 (en) 2016-11-24
WO2014075035A1 (en) 2014-05-15
US20150246023A1 (en) 2015-09-03
US9149464B2 (en) 2015-10-06
US9630926B2 (en) 2017-04-25
IL238662A (en) 2017-08-31
CA2890462A1 (en) 2014-05-15
US20170182008A1 (en) 2017-06-29
IL238662A0 (en) 2015-06-30
US20160289198A1 (en) 2016-10-06
US9452988B2 (en) 2016-09-27
JP2015536996A (ja) 2015-12-24
AR093457A1 (es) 2015-06-10
HK1212977A1 (zh) 2016-06-24
EA201590925A1 (ru) 2015-09-30
CL2015001246A1 (es) 2016-01-15
US20150274675A1 (en) 2015-10-01
KR20150086308A (ko) 2015-07-27
US20180147186A1 (en) 2018-05-31
MX2015005805A (es) 2016-04-15
PH12015501024A1 (en) 2015-07-27
AU2013342015A1 (en) 2015-05-28
HK1215701A1 (zh) 2016-09-09
US20150232427A1 (en) 2015-08-20
US9150517B2 (en) 2015-10-06
TWI598341B (zh) 2017-09-11
BR112015010501A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1212977A1 (zh) 苯達莫司汀衍生物及其使用方法
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
EP2938341A4 (en) Heterocyclic compounds and methods for the use thereof
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
EP2897855A4 (en) FOLDING BIKE AND METHOD OF USE
EP2806872A4 (en) BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
FI2827862T3 (fi) Bendamustiinin formulaatioita
HK1222129A1 (zh) 脱氧野尻霉素衍生物及其使用方法
EP2919983A4 (en) ARTICLES WITH FIBER-REINFORCED POLYMERS AND METHOD OF USE THEREOF
HK1198833A1 (en) N-acylpeptide derivatives and their uses n-
EP2904881A4 (en) ILLUMINATES AND METHOD FOR USE THEREOF
HK1204473A1 (en) Methods of making and using nanostructures
HK1205695A1 (en) Paramyxovirus and methods of use
IL234080A (en) Tetrazolylhydroxyimino derivatives and methods for their production
IL238934A0 (en) Methods for the preparation of phenyloxymethyl-nitro-imidazole derivatives and their use
EP2870133A4 (en) TETRAHYDRO ISOHUMULOD DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF
GB201204455D0 (en) Barrier means and method of use thereof